Impurities in compounded tirzepatide + B12 (Lilly) + quality failures + generic semaglutide + dosing/discontinuation risks [developing]
Key Questions
What safety issues are reported with compounded GLP-1 drugs like tirzepatide?
Eli Lilly reported impurities and liver failure risks in compounded tirzepatide with B12 in March 2026, alongside 60 failed samples in February. Compounded versions from spas and telehealth lack safety oversight, with 1 in 8 adults trying unregulated options.
What are the risks of dosing and discontinuing generic semaglutide?
Dosing escalations can lead to muscle loss, nausea, sarcopenia, and weight regain upon discontinuation, which reverses benefits. Guidance recommends FDA-approved products, supervised microdose tapers, and lifestyle verification.
How can patients safely use GLP-1 medications?
Stick to FDA-approved options, monitor for recalls and price wars, and report issues via MedWatch or AEMS. Avoid unregulated compounded GLP-1s due to quality failures in generics like Dr. Reddy’s.
Eli Lilly (2026-03-13) impurities/liver failure; Feb 60 failed samples; Dr. Reddy’s generic; spa/telehealth compounded GLP-1 lacks safety (1/8 adults tried, 20% unregulated); dosing escalator pitfalls (muscle loss/nausea/sarcopenia/weight regain); discontinuation reverses benefits. Guidance: FDA-approved/verify lifestyle/microdose taper supervised/MedWatch/AEMS; monitor recalls/price wars.